Rare Disease Report sat down with AdAlta CEO Sam Cobb to discuss the impetus for the redesign of AD-214, and what it means for those in the idopathic pulmonary fibrosis.
Sam Cobb
Advertisement
Articles by Sam Cobb
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
The HCPFive: Top News for Healthcare Providers from the Week of 07/12
2
New Dyslipidemia Guidelines Reveal Significant Gap in LDL-C and LLT Treatment Goals
3
Agios Ends Tebapivat Development in Sickle Cell Disease After Phase 2
4
Millions of New Patients Eligible for Statins Under 2026 AHA/ACC Guidelines
5